REFERENCES
1. Durham BH. Molecular characterization of the histiocytoses: Neoplasia
of dendritic cells and macrophages. Semin Cell Dev Biol .
2019;86:62-76.
2. Maeda N, Morimoto A, Shioda Y, et al. Long-term outcomes of children
with extracutaneous juvenile xanthogranulomas in Japan. Pediatr
Blood Cancer . 2020;67:e28381.
3. Emile JF, Abla O, Fraitag S, et al. Revised classification of
histiocytoses and neoplasms of the macrophage-dendritic cell lineages.Blood 2016;127:2672-2681.
4. Cohen Aubart F, Idbaih A, Emile JF, et al.
Histiocytosis and the
nervous system: from diagnosis to targeted therapies. Neuro
Oncol . 2021;23:1433-1446.
5. Héritier S, Barkaoui MA, Miron J, et al.
Incidence and risk
factors for clinical neurodegenerative Langerhans cell histiocytosis: a
longitudinal cohort study. Br J Haematol . 2018;183:608-617.
6. Kinehara T, Umeda K, Saida S, et al. Disseminated xanthogranuloma
with multiple lesions of the central nervous system. Jpn J Pediatr
Hematol Oncol . 2016;53:152-157
[Article in Japanese].
7. Kudo K, Toki T, Kanezaki R, et al. BRAF V600E-positive cells
as molecular markers of bone marrow disease in pediatric Langerhans cell
histiocytosis. Haematologica . 2022;107:1719-1725.
8. Shimizu S, Sakamoto K, Kudo K, et al.
Detection of BRAF V600E
mutation in radiological Langerhans cell histiocytosis-associated
neurodegenerative disease using droplet digital PCR analysis. Int
J Hematol . 2023;118:119-124.
9. Picarsic J, Pysher T, Zhou H, et al. BRAF V600E mutation in Juvenile
Xanthogranuloma family neoplasms of the central nervous system
(CNS-JXG): A revised diagnostic algorithm to include pediatric
Erdheim-Chester disease. Acta Neuropathol Commun . 2019; 7:168.
10. Kim S, Lee M, Shin HJ, et al. Coexistence of intracranial Langerhans
cell histiocytosis and Erdheim-Chester disease in a pediatric patient: a
case report. Childs Nerv Syst . 2016;32:893-896.
11. Martin JM,
Jordá
E,
Martín-Gorgojo
A, et al. Histiocytosis with mixed cell populations. J Cutan
Pathol . 2016;43:456-460.
12. Yeh EA, Greenberg J, Abla O, et al.
Evaluation and
treatment of Langerhans cell histiocytosis patients with central nervous
system abnormalities: Current views and new vistas. Pediatr Blood
Cancer . 2018;65.
13. Imashuku S, Fujita N, Shioda Y, et al.
Follow-up of pediatric
patients treated by IVIG for Langerhans cell histiocytosis (LCH)-related
neurodegenerative CNS disease. Int J Hematol . 2015;101:191-197.
14. Allen CE, Flores R, Rauch R, et al. Neurodegenerative central
nervous system Langerhans cell histiocytosis and coincident
hydrocephalus treated with vincristine/cytosine arabinoside.Pediatr Blood Cancer . 2010;54:416-423.
15. Ehrhardt MJ, Karst J, Donohoue PA, et al. Recognition and treatment
of concurrent active and neurodegenerative langerhans cell
histiocytosis: a case report. J Pediatr Hematol Oncol .
2015;37:e37-40.
16. McClain KL, Picarsic J, Chakraborty R, et al. CNS Langerhans cell
histiocytosis: Common hematopoietic origin for LCH-associated
neurodegeneration and mass lesion. Cancer 2018;124:2607-2620.